

## INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

SERIAL NO.

620-454

SERIAL NO. **10/591847**  
unknown

**APPLICANT**

HOF LAND et al.

(Use several sheets if necessary)

FILING DATE

TC/A.U.

September 5, 2006

unknown

1623

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

/G.K./	International Search Report of PCT/IB2005/000670, mailed 6 April 2006
	SCHROEDER et al., "Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent", Cancer Chemotherapy and Pharmacology, Vol. 53, No. 1, January 2004, Pgs. 91-93, XP008061658
	SCHROEDER et al., "Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide", Cancer Chemotherapy and Pharmacology, Vol. 52, No. 2, August 2003, Pgs. 167-174, XP008061654
	HOLM B et al., "Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supra-lethal doses of etoposide and teniposide", Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, June 1998, Vol. 4, No. 6, June 1998, Pgs. 1367-1373, XP002373086
	JENSEN et al., "DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide", Biochemical Pharmacology, 1 October 1997, Vol. 54, No. 7, Pgs. 755-759, XP008061671
	HOLM BENTE et al., "ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors", Cancer Chemotherapy and Pharmacology, Vol. 38, No. 3, 1996, Pgs. 203-209, XP008061672
/G.K./	MINEHAN KERN et al., "The interaction of etoposide with radiation: Variation in cytotoxicity with the sequence of treatment", Life Sciences, Vol. 53, No. 15, 1993, Pgs. 237-242, XP008061879

**\*Examiner**

/Ganapathy Krishnan/

Date Considered

08/15/2008